Article Text

Download PDFPDF
Case report
Primary osteosarcoma of the skull in teenager
  1. Liliana Vasquez1,2,
  2. Victor Tejada3,
  3. Ivan Maza1 and
  4. Ronald Mendoza4
  1. 1 Pediatric Oncology, Rebagliati Hospital, Lima, Peru
  2. 2 Centro de Investigación de Medicina de Precisión, Universidad de San Martin de Porres Facultad de Medicina Humana, La Molina, Lima, Peru
  3. 3 Department of Head and Neck Surgery, Rebagliati Hospital, Lima, Peru
  4. 4 Department of Pathology, Rebagliati Hospital, Lima, Peru
  1. Correspondence to Dr Liliana Vasquez, lilianavasq{at}


Osteosarcoma of the skull is a rare primary malignant bone tumour in children, representing 1–2% of all cranial tumours. We describe a case of a 17-year-old adolescent with chondroblastic osteosarcoma of the parietal-occipital bone and no distant metastases at presentation treated with neoadjuvant chemotherapy, surgery and, later, concurrent chemoradiotherapy. The patient suffered progressive disease and died 15 months after diagnosis. There are at least 15 paediatric cases of osteosarcoma of the skull described in the literature. Due to its rarity, there are no broad prospective studies on this entity, which has distinctive features when compared to other craniofacial tumours, carrying a worse prognosis. Complete surgical resection is needed for long-term survival, whereas chemotherapy and radiotherapy have still questionable indications.

  • paediatric oncology
  • chemotherapy

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Contributors LV, IM and VT conceived of the presented idea and treated the patient. LV, RM and VT verify the images and content of this work. All authors discussed the results and contributed to the final manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Patient consent for publication Obtained.